ABBV AbbVie, Inc.

Price (delayed)

$98.88

Market cap

$146.02B

P/E Ratio

17.44

Dividend/share

$4.5

EPS

$5.67

Enterprise value

$171.92B

Business Summary

Sector: Healthcare
Industry: Drug Manufacturers - General
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Highlights

The EPS has soared by 58% YoY and by 7% from the previous quarter
The company's net income has surged by 57% YoY and by 7% QoQ

Key stats

Shares outstanding
1.48B
Market cap
$146.02B
Enterprise value
$171.92B
EBIT
$10.59B
EBITDA
$12.67B
Price to earnings (P/E)
17.44
Price to book (P/B)
N/A
Price to sales (P/S)
4.3
EV/EBIT
16.23
EV/EBITDA
13.57
Net debt/EBITDA
2.05
EV/Sales
5.05
EBITDA margin
37.2%
Gross margin
77.4%
Net margin
24.8%
Operating margin
39.9%
Return on assets
11.4%
Return on equity
N/A
Return on invested capital
20.7%
Return on capital employed
14.2%
Return on sales
31.1%
Debt to equity
-9.04
Free cash flow
$13.55B
Free cash flow per share
$9.15
Book value per share
-$5.01
Revenue per share
$23
TBVPS
$38.78
Current ratio
3.14
Quick ratio
2.88
Working capital
$35.29B
Dividend yield
4.55%
DPS
$4.5
Payout ratio
79.4%

ABBV stock price

Financial performance

The operating income has soared by 109% YoY and by 4.6% from the previous quarter
The operating margin has surged by 101% year-on-year and by 2.3% since the previous quarter
The company's net income has surged by 57% YoY and by 7% QoQ
The net margin has surged by 51% year-on-year and by 4.6% since the previous quarter

Valuation

Price to earnings (P/E)
Current price to earnings (P/E):
17.44
The EPS has soared by 58% YoY and by 7% from the previous quarter
ABBV's P/E is 22% below its last 4 quarters average of 22.3 and 19% below its 5-year quarterly average of 21.4
Price to book (P/B)
Current price to book (P/B):
N/A
AbbVie Inc's equity has increased by 9% from the previous quarter and by 5% YoY
Price to sales (P/S)
Current price to sales (P/S):
4.3
ABBV's P/S is 23% above its last 4 quarters average of 3.5 and 2.4% above its 5-year quarterly average of 4.2
ABBV's revenue is up by 4.3% year-on-year and by 2.4% since the previous quarter

Efficiency

The ROS has soared by 65% YoY and by 4% from the previous quarter
AbbVie Inc's return on assets has increased by 30% YoY but it has decreased by 5% QoQ
AbbVie Inc's ROIC has increased by 29% YoY but it has decreased by 8% from the previous quarter

Dividends

DPS
$4.5
Dividend yield
4.55%
Payout ratio
79.4%

Recent dividends

Financial health

Assets vs liabilities
AbbVie Inc's total assets is 8% lower than its total liabilities
AbbVie Inc's total assets has surged by 61% YoY and by 2.3% QoQ
Debt vs equity
The company's debt to equity has shrunk by 90% YoY and by 11% QoQ
AbbVie Inc's equity has increased by 9% from the previous quarter and by 5% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.